Neoadjuvant abiraterone with or without cabazitaxel prior to radical prostatectomy (RP) for high-risk prostate cancer demonstrated beneficial effects in a phase 2 trial, investigators reported at the ASCO Genitourinary Cancers Symposium 2022.
As part of the ACDC-RP trial, investigators randomly assigned 78 men with high-risk prostate cancer to receive either abiraterone + prednisone + leuprolide + cabazitaxel (arm A) or abiraterone + prednisone + leuprolide (arm B) for 6 months prior to RP. The primary outcome was the rate of pathologic complete response (CR) or minimal residual disease (MRD), defined as 5% or less of prostate volume involved by tumor.
Of the 78 men, 70 completed the full course of study treatment and underwent RP: 38 in arm A and 32 in arm B. Across both study arms, 31 men (44%) achieved either CR or MRD, Neil E. Fleshner, MD, of Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, reported on behalf of his research team.
Overall, 5 men had CR (2 in arm A) and 26 had MRD (15 in arm A). The difference between study arms was not statistically significant. The treatment groups had similar biochemical-free survival (BFS) rates. Patients who achieved CR or MRD had significantly longer BFS.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Fleshner NE, Hansen AR, Chin J, et al. Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP. Presented at ASCO GU 2022; February 17-19, 2022. Abstract 224.
This article originally appeared on Renal and Urology News